An interventional study of CytoSorb and VA-ECMO only in Cardiogenic Shock, sponsored by Christian Schulze. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Christian Schulze · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2021, is one of 13 with no phase, and was the 19th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:
Leipzig Heart Science gGmbH · Sites in Germany
Ages 18–80
University Hospital of Cologne · Sites in Germany
Ages 18–77
4TEEN4 Pharmaceuticals GmbH · Sites in Germany, Armenia, Belgium and 6 more countries
Ages 18–80
Abiomed Inc. · Sites in Germany, Italy, Switzerland
Ages 18+
University Heart Center Freiburg - Bad Krozingen · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 60 across the 22 interventional studies, 138 across the 14 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
Christian Schulze is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Christian Schulze has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Cardiogenic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT06308055Abiomed Inc.Abiomed Impella RT-DAQ - Observational Study | 2027-06-30 |
| NCT07515508University Heart Center Freiburg - Bad KrozingenMultimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE | 2027-07-31 |
| NCT07687017Leipzig Heart Science gGmbHCRP Apheresis in Infarct-Related Cardiogenic Shock | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the ECMOsorb study the impact of a veno-arterial -ECMO in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock is to be examined
The prospective, interventional, randomised controlled and blinded ECMOsorb study investigates in critically ill patinets with cardiogenic shock and with veno-arterial ECMO (VA-ECMO) treatment the impact of an extracorporeal cytokin hemadsorption system on hemodynamics, defined by the Inotropic Score 72 hours after initiation of the adsorber (intervention) or normal ECMO tube (control) in the VA-ECMO.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
standard ICU care WITH CytoSorb
Device: CytoSorb
standard ICU care WITHOUT CytoSorb
Other: VA-ECMO only
An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
Also known as: Standard ICU care (with VA-ECMO) AND CytoSorb Adsorber
only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
Also known as: Standard ICU care (with VA-ECMO)
Change in inotropic score after 72h (difference between the two study groups)
Inotropic Score: dopamine dose \[μg/kg/min\] + dobutamine dose \[μg/kg/min\] + 100x epinephrine dose \[μg/kg/min\] + 100x norepinephrine \[μg/kg/min\]
Time frame: 72 hours
Interleukin 6
pg/ml
Time frame: 0 to 7 days after beginning of intervention
Procalcitonin
ng/ml
Time frame: 0 to 7 days after beginning of intervention
c-reactive protein
mg/l
Time frame: 0 to 7 days after beginning of intervention
lactate
mmol/l
Time frame: 0 to 7 days after beginning of intervention
creatinine
µmol/l
Time frame: 0 to 7 days after beginning of intervention
glomerular filtration rate (GFR)
ml/min
Time frame: 0 to 7 days after beginning of intervention
troponin
pg/ml
Time frame: 0 to 7 days after beginning of intervention
creatinine kinase
µmol/l\*s
Time frame: 0 to 7 days after beginning of intervention
myoglobine
µg/l
Time frame: 0 to 7 days after beginning of intervention
urinary output
ml/h
Time frame: 0 to 7 days after beginning of intervention
neuron specific enolase
µg/l
Time frame: 0 to 7 days after beginning of intervention
s-100
µg/l
Time frame: 0 to 7 days after beginning of intervention
cystatin c
mg/l
Time frame: 0 to 7 days after beginning of intervention
galectin-3
ng/ml
Time frame: 0 to 7 days after beginning of intervention
Duration of: renal replacement therapy (CVVHD), mechanical ventilation, ECMO therapy, inotropic /vasopressor treatment
hours
Time frame: day 30 after beginning of intervention
30 day, ICU and in-hospital mortality
nominal scale (yes/no)
Time frame: day 30 after beginning of intervention
Length of stay in ICU and total length of hospital stay until discharge/transfer
hours
Time frame: day 30 after beginning of intervention
Necessary Implantation of an Active Assist Device or heart transplantation
nominal scale (yes/no)
Time frame: day 30 after beginning of intervention
SAPS II
Simplified Acute Physiology Score II (Minimum value: 0 / maximum value: 163; higher values means worse outcome)
Time frame: 0 to 7 days after beginning of intervention
APACHE II score
Acute Pysiology and Chronic Health Evaluation II (Minimum value: 0 / maximum value: 71; higher values means worse outcome)
Time frame: 0 to 7 days after beginning of intervention
SOFA score
Sequential Organ Failure Assessment Score (Minimum value: 0 / maximum value: 24; higher value means worse outcome)
Time frame: 0 to 7 days after beginning of intervention
cerebreal performance category (CPC)
CPC 1 (adequate function) to CPC 5 (brain dead)
Time frame: 0 to 30 days after beginning of intervention
Glasgow coma scale (GCS)
Assessment scheme for disorders of consciousness and brain function (eyes, verbal, motor); scale from 3 (severe impairment) to 15 points (no abnormalities)
Time frame: 0 to 30 days after beginning of intervention
EuroQuol 5D-3L Descriptive System
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems.
Time frame: 7 to 30 days after beginning of intervention
EQ VAS
EQ visual analogue scale (EQ VAS), patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.
Time frame: 7 to 30 days after beginning of intervention
Modified Rankin scale
scale from 0 (no symptoms) to 6 (dead);
Time frame: 0 to 30 days after beginning of intervention
Measurement of right ventricular parameters
measurements of right ventricular function in the echo (TAPSE in mm; FAC in %; RVEDD in mm; sPAP in mmHg; RA area in cm²; TASV in cm/s; ICV in mm)
Time frame: 0 to 7 days after beginning of intervention
Measurement of left ventricular parameters
measurements of left ventricular function in the echo (LVEDD in mm; LVESD in mm; LVEF in %; VSD (yes/no); LVEDV in ml; LVESV in ml; GLS in %; LA volume in ml)
Time frame: 0 to 7 days after beginning of intervention
Measurement of kidney injury and kidney function
NGAL, KIM-1, L-FABP, IGFBP7 in ng/ml
Time frame: 0 to 7 days after beginning of intervention
Interleukin 18
pg/ml
Time frame: 0 to 7 days after beginning of intervention
incidence of apoplexy
nominal scale (yes/no)
Time frame: 30 days after beginning of intervention
mean arterial pressure
mmHg
Time frame: 0 to 7 days after beginning of intervention
central venous oxygen saturation
in %
Time frame: 0 to 7 days after beginning of intervention
mixed venous oxygen saturation
in %
Time frame: 0 to 7 days after beginning of intervention
arterial oxygen saturation
in %
Time frame: 0 to 7 days after beginning of intervention
heart failure re-hospitalisation
nominal scale (yes/no)
Time frame: 30 days after beginning of intervention
Brain natriuretic peptide (BNP)
pg/ml
Time frame: 0 to 7 days after beginning of intervention
n-terminal pro brain natriuretic peptide (NT-proBNP)
pg/ml
Time frame: 0 to 7 days after beginning of intervention
Ran from May 2021 to primary completion in Dec 2025, 55 months.
Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 55 months is above that.
Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Christian Schulze